Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.55 |
| ▸ | TLR2 | O60603 | 3/20 | 0.54 |
| ▸ | MDM4 | O15151 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1738761 | 1.00 | KMT2A (0.56) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL31437099 | 1.00 | KMT2A (0.56) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL29401421 | 1.00 | KMT2A (0.56) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL31437131 | 1.00 | KMT2A (0.56) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL25357584 | 0.97 | MDM2 (0.56) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL25357589 | 0.97 | MDM2 (0.56) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL5495444 | 0.92 | FOLH1 (0.57) | KMT2AMDM2 | |
| SCHEMBL260631 | 0.92 | KMT2A (0.66) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL178698 | 0.92 | KMT2A (0.66) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL178733 | 0.92 | KMT2A (0.66) | KMT2AMDM2TLR2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345917-B1 | ANTIPROTOZOAL COMPOUNDS | BACOBA AG (CH) | 2021-11-17 | — | — | EP | disclosed |
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | KMT2A 4176/4885MDM2 1236/4885TLR2 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.